A--National Gene Vector Biorepository (NGVB)
ID: 75N92025R00003Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NHLBIBETHESDA, MD, 20892, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; APPLIED RESEARCH (AN22)

Original Source

https://sam.gov/opp/032d1191d9064d9fb5e7bc284eaa5214/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is preparing to issue a Request for Proposals (RFP) for the National Gene Vector Biorepository (NGVB) program, aimed at supporting translational gene therapy research over a five-year period. The selected contractor will be tasked with archiving over 20,000 clinical specimens under Good Laboratory Practices (GLP), developing assays for clinical testing, and maintaining a user-friendly web-based catalogue for gene therapy reagents, all while ensuring compliance with FDA regulations. This initiative underscores the government's commitment to advancing gene therapy research and enhancing the services provided by the NGVB. Interested parties should note that the RFP details are expected to be released on November 22, 2024, and can contact Ethan J. Mueller at ethan.mueller@nih.gov or +1 301 496 2153 for further information.

    Point(s) of Contact
    MUELLER, ETHAN J
    +1 301 496 2153
    ethan.mueller@nih.gov
    Files
    Title
    Posted
    Attachment_11_-_Pre-sol-notice_1.doc
    The National Heart, Lung, and Blood Institute (NHLBI) released a Pre-Solicitation Notice for RFP No. 75N92025R00003 that invites a contractor to support the National Gene Vector Biorepository (NGVB) program over a five-year period. The NGVB provides essential resources for translational gene therapy research, offering services that enable compliance with FDA regulations. Its offerings include a reagent repository, pharmacology and toxicology resources, analysis of clinical trial specimens, and archiving services. The contractor will be responsible for a range of tasks, such as archiving over 20,000 clinical specimens under Good Laboratory Practices (GLP), developing necessary assays for clinical testing, and maintaining a user-friendly web-based catalogue for gene therapy reagents. The announcement emphasizes that this is not a contract solicitation but rather a notice of intent to issue one, with RFP details anticipated to be available on November 22, 2024. This initiative signifies the government’s commitment to advancing gene therapy research aligned with FDA requirements while enhancing the portfolio of services provided by the NGVB.
    Lifecycle
    Title
    Type
    A--National Gene Vector Biorepository (NGVB)
    Currently viewing
    Presolicitation
    Similar Opportunities
    Scientific Management and Support to the National Institute of Mental Health (NIMH) Repository and Genomics Resource (NRGR)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for scientific management and support services for the National Institute of Mental Health Repository and Genomics Resource (NRGR). The objective of this procurement is to sustain, enhance, and enrich the NRGR, which provides critical biospecimens and genomic data for research on psychiatric disorders, thereby facilitating a deeper understanding of the genetic factors involved in mental health. This initiative is vital for advancing both basic and translational research in the field of mental health, ensuring broad access to valuable resources for researchers. Proposals are due by November 21, 2024, and must be submitted electronically via the NIH's eCPS system; interested parties can contact Sarah Adan at sarah.adan@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    A--NIH NeuroBioBank Brain and Tissue Repository
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for the establishment of the NIH NeuroBioBank Brain and Tissue Repository. The objective of this procurement is to create and manage contract collection sites for acquiring, storing, and distributing human brain and central nervous system tissues for research purposes, aimed at advancing the understanding of nervous system disorders. This initiative is critical for enhancing biomedical research by providing well-characterized specimens to researchers, thereby facilitating studies that could lead to improved treatments and interventions. Proposals are due by November 25, 2024, with the anticipated contract performance period starting on May 1, 2025, and extending potentially through multiple option years. Interested vendors should contact Robin D. Knightly at robin.knightly@nih.gov or call +1 301 827 5302 for further information.
    SOURCES SOUGHT: Long read sequencing services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to provide long read sequencing services as part of the Global Parkinson’s Genetics Program (GP2). The objective is to genotype over 150,000 individuals worldwide to enhance understanding of genetic risk factors associated with Parkinson’s Disease, requiring the contractor to perform long read sequencing on 500 human genomic DNA samples with a minimum coverage of 25X per sample, alongside ancillary services such as DNA fragmentation, library preparation, and bioinformatics support. Interested parties must submit their capability statements by November 15, 2024, at 9:00 AM Eastern Time, to Rashiid Cummins at rashiid.cummins@nih.gov, ensuring compliance with the specified guidelines and format.
    Reagent Generation for Bioanalytical Method Development on Biologics
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified sources for a potential contract focused on reagent generation for bioanalytical method development related to biologics. The primary objective is to obtain information on the availability and capability of companies to generate and deliver reagents, including anti-drug antibodies, that support the quantification of novel biologic drugs in various biological matrices. This initiative is crucial for advancing drug development processes and improving success rates in preclinical stages, with the Therapeutic Development Branch (TDB) at NIH playing a pivotal role in moving therapeutic candidates through the drug development pipeline. Interested parties must submit their capability statements by November 8, 2024, to Nick Niefeld at nick.niefeld@nih.gov, referencing sources sought notice number 75N95025R00007.
    Revio reagent kit, 24pack All reagents for sequenc
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to procure the Revio reagent kit, which includes a 24-pack of all reagents necessary for sequencing 24 Revio SMRT Cells. This solicitation aims to acquire essential laboratory supplies that are critical for advanced genomic sequencing applications. The Revio reagent kit plays a vital role in supporting research and development in the field of genomics and personalized medicine. Interested vendors can reach out to Dorothy L. Maxwell at dorothy.maxwell@nih.gov or call 301-827-7729 for further details regarding the procurement process.
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Active
    Health And Human Services, Department Of
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.
    BIO-RAD LABORATORIES, INC. CSP, QX200 DIGITAL PCR W/ADG OS DIGITAL PCR SYSTEMS W/AUTO DG SERVICE CONTRACT
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is planning to award a sole source fixed-price contract to Bio-Rad Laboratories, Inc. for a service contract related to two QX200 AutoDG ddPCR Systems. The contract will cover a twelve-month base year with four additional option years, focusing on essential maintenance and support services to ensure compliance with FDA regulations and optimal operational performance of the equipment. These systems are critical for assessing gene modification efficiency in cellular therapy products, which directly impacts treatment decisions and patient outcomes. Interested parties may express their interest and capabilities to Tasha Lowe at lowet2@mail.nih.gov by November 9, 2024, at 12 PM, as the government retains discretion over the procurement process.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Control (CMC) services related to the development of drug substances under RFP number 75N95024R00094. The primary objective is to secure high-quality drug substances to support preclinical and Investigational New Drug (IND)-enabling studies, ensuring compliance with current Good Manufacturing Practices (cGMP) and federal regulations. This initiative is crucial for advancing therapeutic innovations and facilitating collaborations in drug development, with a total funding amount of up to $49.7 million over the contract period from September 1, 2025, to May 14, 2031. Interested parties must submit their proposals by December 3, 2024, and can direct inquiries to primary contact Samson Shifaraw at samson.shifaraw@nih.gov or secondary contact Valerie Whipple at valerie.whipple@nih.gov.
    PREPARATION AND DISTRIBUTION OF RESEARCH DRUG PRODUCTS
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), is seeking proposals for the "Preparation and Distribution of Research Drug Products" under solicitation number 75N95024R00003. The primary objective of this procurement is to acquire, analyze, create, and distribute a variety of drug compounds essential for drug abuse and addiction research, including controlled and uncontrolled substances, while ensuring compliance with DEA regulations. This contract, structured as an indefinite delivery, indefinite quantity (IDIQ) agreement for a five-year period, aims to enhance research capabilities in the field of drug abuse, with proposals due by November 15, 2024, at 1:00 PM (Eastern Time). Interested parties should contact Scott Duernberger at scott.duernberger@nih.gov or Josh Lazarus at josh.lazarus@nih.gov for further information.
    Democratized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Democratized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic. This initiative aims to enhance access to clinically validated curative cell therapies for pediatric patients with rare genetic diseases by advancing quality assurance mechanisms at Academic Medical Centers. The program focuses on developing innovative solutions for small-batch manufacturing of autologous cell therapies, addressing production variability, regulatory challenges, and market failures in this critical healthcare area. Proposals are due by November 18, 2024, at 12 PM EST, with the final solicitation released on October 22, 2024. Interested parties can reach out to the designated contact via the provided email for further inquiries.